FDA approved new oral therapy: Delay functional decline of ALS by 33%
- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
- NK Cells: Unveiling a Multifaceted Medical Marvel for Stroke Recovery and Beyond
- Japan’s Shift to Regular COVID-19 Vaccination for Elderly
- Active Monitoring vs. Surgery for Moderate Cervical Lesions
- Probiotics Linked to Immune Suppression and Tumor Growth
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
FDA approved new oral therapy: Delay functional decline of ALS by 33%
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA approved new oral therapy: Delay functional decline of ALS by 33%.
On May 14, Mitsubishi Tanabe Pharma America (MTPA) announced that the U.S. FDA has approved the marketing of oral Edaravone (Brand name Radicava ORS) for the treatment of amyotrophic lateral sclerosis (ALS). This is a rapidly progressive neurodegenerative disease that currently has no cure.
In a pivotal clinical trial, Radicava ORS demonstrated the same efficacy in slowing physical decline compared to an FDA-approved intravenous formulation.
According to the press release, the oral formulation provides ALS patients with a flexible way of administering medication, either orally or through a feeding tube, and does not require dose adjustments.
ALS is a neurodegenerative disease in which muscle function is lost due to the death of motor neurons in the brain and spine.
Patients have an average life expectancy of 2 to 5 years after diagnosis, and treatment options are currently lacking.
The intravenous dosage form of Edaravone was approved by the US FDA in 2017. Its mechanism of action is still not fully elucidated and is thought to delay disease progression by reducing oxidative stress. Radicava ORS is an oral formulation made for ALS patients.
It is a 5 mL liquid formulation that can be taken orally using a syringe or infused into a feeding tube, and does not require refrigeration or be dissolved prior to use. With proper instruction, medical staff can administer the drug in just a few minutes.
The FDA approval is supported by multiple studies, including a pivotal Phase 3 clinical study evaluating 137 ALS patients. Trial results showed that after 24 weeks of treatment, Radicava ORS slowed the decline of physical function in patients by 33% compared with placebo.
▲ Phase 3 clinical trial results of Radicava ORS (Image source: Reference [2])
References:
[1] Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA ORS® (Edaravone) for the Treatment of ALS. Retrieved May 13, 2022, from https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma- america-announces-fda-approval-of-radicava-ors-Edaravone-for-the-treatment-of-als-301546937.html
[2] Radicava ORS. Retrieved May 13, 2022, from https://www.multivu.com/players/English/9019751-mitsubishi-tanabe-pharma-america-fda-approval-radicava-ors/docs/ProductFactSheetPDF_1652425733568-13550661 .pdf
FDA approved new oral therapy: Delay functional decline of ALS by 33%
(source:internet, reference only)
Disclaimer of medicaltrend.org
